
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
1 Departments of Cancer and Thoracic Surgery and 2 Molecular Genetics, Graduate School of Medicine and Dentistry, Okayama University, Okayama, Japan, and 3 Hamon Center for Therapeutic Oncology Research and 4 Departments of Pathology and 5 Urology, University of Texas Southwestern Medical Center, Dallas, Texas
Purpose: Human DOC-2/DAB2 interactive protein (hDAB2IP) gene is a novel member of the Ras GTPase-activating family and has been demonstrated to be a tumor suppressor gene inactivated by methylation in prostate cancer. We analyzed methylation and expression status of hDAB2IP in breast cancer.
Experimental Design: The promoter region of hDAB2IP was divided into two regions (m2a and m2b) following our previous report on prostate cancer, and methylation status was determined in breast cancer cell lines with bisulfited DNA sequencing. Expression was semiquantified with real-time reverse transcription-PCR to find that aberrant methylation showed the inverse relationship with expression. On the basis of sequence data, we developed methylation-specific PCR for m2a and m2b regions and applied to samples.
Results: Aberrant methylation was detected in 11 of 25 breast cancer cell lines (44%) and 15 of 39 primary tumors (38%) at the m2a region and in 12 of 25 cell lines (48%) and 13 of 39 tumors (33%) at the m2b region. In addition, gene expression was restored in methylated cell lines with 5-aza-2'-deoxycytidine, confirming that methylation caused gene down-regulation. We also examined the relationship between hDAB2IP methylation and clinicopathologic features in primary tumors and found that methylation in the m2b region was associated with progressive nodal status of tumors.
Conclusions: We developed methylation-specific PCR for hDAB2IP and examined its methylation status in breast cancer. Our results demonstrate that hDAB2IP methylation frequently is present in breast cancer and plays a key role in hDAB2IP inactivation, suggesting the relationship between hDAB2IP methylation and lymph node metastasis of breast cancer.
This article has been cited by other articles:
![]() |
K. Misawa, Y. Ueda, T. Kanazawa, Y. Misawa, I. Jang, J. C. Brenner, T. Ogawa, S. Takebayashi, R. A. Grenman, J. G. Herman, et al. Epigenetic Inactivation of Galanin Receptor 1 in Head and Neck Cancer Clin. Cancer Res., December 1, 2008; 14(23): 7604 - 7613. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-T. Hsieh, J. A. Karam, and W. Min Genetic and Biologic Evidence that Implicates a Gene in Aggressive Prostate Cancer J Natl Cancer Inst, December 19, 2007; 99(24): 1823 - 1824. [Full Text] [PDF] |
||||
![]() |
H. Jin, X. Wang, J. Ying, A. H. Y. Wong, Y. Cui, G. Srivastava, Z.-Y. Shen, E.-M. Li, Q. Zhang, J. Jin, et al. Epigenetic silencing of a Ca2+-regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers PNAS, July 24, 2007; 104(30): 12353 - 12358. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Engelmark, E. L. Ivansson, J. J. Magnusson, I. M. Gustavsson, A. H. Beskow, P. K.E. Magnusson, and U. B. Gyllensten Identification of susceptibility loci for cervical carcinoma by genome scan of affected sib-pairs Hum. Mol. Genet., November 15, 2006; 15(22): 3351 - 3360. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Chen, S.-w. Tu, and J.-T. Hsieh Down-regulation of Human DAB2IP Gene Expression Mediated by Polycomb Ezh2 Complex and Histone Deacetylase in Prostate Cancer J. Biol. Chem., June 10, 2005; 280(23): 22437 - 22444. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |